l-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial

BACKGROUND Centenarians are characterized by weakness, decreasing mental health, impaired mobility, and poor endurance. L-Carnitine is an important contributor to cellular energy metabolism. OBJECTIVE This study evaluated the efficacy of L-carnitine on physical and mental fatigue and on cognitive functions of centenarians. DESIGN This was a placebo-controlled, randomized, double-blind, 2-phase study. Sixty-six centenarians with onset of fatigue after even slight physical activity were recruited to the study. The 2 groups received either 2 g levocarnitine once daily (n = 32) or placebo (n = 34). Efficacy measures included changes in total fat mass, total muscle mass, serum triacylglycerol, total cholesterol, HDL cholesterol, LDL cholesterol, Mini-Mental State Examination (MMSE), Activities of Daily Living, and a 6-min walking corridor test. RESULTS At the end of the study period, the levocarnitine-treated centenarians, compared with the placebo group, showed significant improvements in the following markers: total fat mass (-1.80 compared with 0.6 kg; P < 0.01), total muscle mass (3.80 compared with 0.8 kg; P < 0.01), plasma concentrations of total carnitine (12.60 compared with -1.70 mumol; P < 0.05), plasma long-chain acylcarnitine (1.50 compared with -0.1 micromol; P < 0.001), and plasma short-chain acylcarnitine (6.0 compared with -1.50 micromol; P < 0.001). Significant differences were also found in physical fatigue (-4.10 compared with -1.10; P < 0.01), mental fatigue (-2.70 compared with 0.30; P < 0.001), fatigue severity (-23.60 compared with 1.90; P < 0.001), and MMSE (4.1 compared with 0.6; P < 0.001). CONCLUSIONS Our study indicates that oral administration of levocarnitine produces a reduction of total fat mass, increases total muscular mass, and facilitates an increased capacity for physical and cognitive activity by reducing fatigue and improving cognitive functions.

[1]  M. Malaguarnera,et al.  L-carnitine reduces severity of physical and mental fatigue and improves daily activities in the elderly. , 2006, Southern medical journal.

[2]  D. Wallace.  A Mitochondrial Paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary Medicine , 2005, Annual review of genetics.

[3]  M. Malaguarnera,et al.  Successful aging in centenarians: myths and reality. , 2005, Archives of gerontology and geriatrics.

[4]  B. Ames,et al.  Comparison of the Effects of l‐Carnitine and Acetyl‐l‐Carnitine on Carnitine Levels, Ambulatory Activity, and Oxidative Stress Biomarkers in the Brain of Old Rats , 2004, Annals of the New York Academy of Sciences.

[5]  A. Virmani,et al.  Role of carnitine esters in brain neuropathology. , 2004, Molecular aspects of medicine.

[6]  L. Thal,et al.  Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease , 2003, International clinical psychopharmacology.

[7]  B. Ames,et al.  Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: Partial reversal by feeding acetyl-l-carnitine and/or R-α-lipoic acid , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Speciale,et al.  Correlation between the bone mass, psychometric performances, and the levels of autonomy and autosufficiency in an elderly Italian population above 80 years of age. , 2001, Archives of gerontology and geriatrics.

[9]  J. Pettegrew,et al.  Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression , 2000, Molecular Psychiatry.

[10]  G. Paradies,et al.  The effect of aging and acetyl‐L‐carnitine on the pyruvate transport and oxidation in rat heart mitochondria , 1999, FEBS letters.

[11]  D. Morris,et al.  The use of the New york heart association's classification of cardiovascular disease as part of the patient's complete problem list , 1999, Clinical cardiology.

[12]  F. Tomasello,et al.  Serum Carnitine Levels in Centenarians , 1999 .

[13]  B. Ames,et al.  Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Malaguarnera,et al.  MYTHOLOGY AND MEDICINE , 1995 .

[15]  Ernesto Quagliariello,et al.  Effect of aging and acetyl‐l‐carnitine on the activity of cytochrome oxidase and adenine nucleotide translocase in rat heart mitochondria , 1994, FEBS letters.

[16]  C. Hoppel,et al.  Effect of intravenous L‐carnitine on carnitine homeostasis and fuel metabolism during exercise in humans , 1994, Clinical pharmacology and therapeutics.

[17]  E. Brass.  Overview of coenzyme A metabolism and its role in cellular toxicity. , 1994, Chemico-biological interactions.

[18]  R. Carrozzo,et al.  Muscle Carnitine Deficiency in Patients With Severe Peripheral Vascular Disease , 1991, Circulation.

[19]  F. Di Lisa,et al.  Transport and functions of carnitine in muscles. , 1990, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[20]  N. Larocca,et al.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.

[21]  J. Regensteiner,et al.  Carnitine and acylcarnitine metabolism during exercise in humans. Dependence on skeletal muscle metabolic state. , 1989, The Journal of clinical investigation.

[22]  S. Wessely,et al.  Fatigue syndromes: a comparison of chronic "postviral" fatigue with neuromuscular and affective disorders. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[23]  B. Rodrigues,et al.  Effect of L-Carnitine Treatment on Lipid Metabolism and Cardiac Performance in Chronically Diabetic Rats , 1988, Diabetes.

[24]  R. R. Brenner.  Los acidos grasos esenciales : sus transformaciones y funciones , 1983 .

[25]  C. Long,et al.  Kinetics of carnitine‐dependent fatty acid oxidation , 1982, Neurology.

[26]  C. Hoppel,et al.  Carnitine metabolism in the fasting rat. , 1978, The Journal of biological chemistry.

[27]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[28]  S. Lindstedt,et al.  A method for the determination of carnitine in the picomole range. , 1972, Clinica chimica acta; international journal of clinical chemistry.

[29]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[30]  P. Ripari,et al.  Influence of L-carnitine administration on maximal physical exercise , 2004, European Journal of Applied Physiology and Occupational Physiology.

[31]  M. Malaguarnera,et al.  Levocarnitine Administration in Elderly Subjects with Rapid Muscle Fatigue , 2003, Drugs & aging.

[32]  G. Lopaschuk,et al.  Uncoupling of contractile function from mitochondrial TCA cycle activity and MVO2 during reperfusion of ischemic hearts. , 1996, The American journal of physiology.

[33]  M. Malaguarnera,et al.  Assessment of self-sufficiency in ultraoctagenerians. , 1996, Archives of gerontology and geriatrics.

[34]  K. Nałęcz,et al.  Carnitine--a known compound, a novel function in neural cells. , 1996, Acta neurobiologiae experimentalis.

[35]  W. Hiatt,et al.  Carnitine metabolism during exercise. , 1994, Life sciences.